glp 1 charlotte nc Health-tech startup Vivoro eyes market gap for GLP-1 meds, more Ballantyne Medical Associates, PLLC |
Description
NAD+ levels decline with age measurably so, beginning in the 30s and accelerating through midlife
The most common scenarios where Qsymia falls short include: BMI above 40, where 10 to 12% weight loss leaves the patient still in severe obesity
Well, sure, of course, the makers of the drug are gonna say it helps
It isnt dying, but it is niche (though very profitable for the incumbents)
